

Sheppard Mullin Advises Tiziana Life Sciences on Follow-on Public Offering

Client to Use Net Proceeds to Expedite Clinical Development for Potential COVID-19 Treatment

03.23.2020

Sheppard Mullin advised Tiziana Life Sciences plc (Nasdaq: TLSA) (AIM: TILS), a U.K. biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, including COVID-19, with its underwritten follow-on public offering of American Depositary Shares on the NASDAQ Global Market, raising approximately \$10 million.

Partner Jeffrey Fessler and associate Justin Anslow represented Tiziana Life Sciences in the public offering.

[Click here to read the press release.](#)

Attorneys

Jeffrey J. Fessler

Practice Areas

Capital Markets

Corporate

Industries

Life Sciences